Orchestra BioMed
OBIO
46 hedge funds and large institutions have $130M invested in Orchestra BioMed in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 7 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0% more funds holding
Funds holding: 46 → 46 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1.93% less ownership
Funds ownership: 58.76% → 56.84% (-1.9%)
15% less capital invested
Capital invested by funds: $154M → $130M (-$23.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Amitell Capital
Singapore
|
+$2.45M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.44M |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
+$2.4M |
| 4 |
AC
Athanor Capital
New York
|
+$726K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$304K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.57M |
| 2 |
AIC
AWM Investment Company
New York
|
-$2.56M |
| 3 |
GL
Governors Lane
New York
|
-$1.68M |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$1.64M |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$1.4M |
OBIO Hedge Fund Activity: Q1 2021 in Review
46 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2021, worth a combined $130M — down 15% from $154M a quarter earlier.
Fund positioning in OBIO was balanced in Q1 2021: 7 funds opened new positions, 7 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Amitell Capital, adding an estimated $2.45M. The largest seller was Wellington Management Group, cutting an estimated $2.57M.
- 46 institutional investors held Orchestra BioMed (OBIO) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $130M of Orchestra BioMed stock for Q1 2021, down 15% quarter-over-quarter.
- 7 funds opened new Orchestra BioMed positions in Q1 2021 and 7 closed out, a net change of 0 holders.
- The largest Orchestra BioMed buyer in Q1 2021 was Amitell Capital, an estimated $2.45M added.
- The largest Orchestra BioMed seller in Q1 2021 was Wellington Management Group, an estimated $2.57M sold.
Based on aggregated 13F filings for Q1 2021.